Prostate cancer - new therapeutic options
This study was published in Cancer 117 (2011) 2419-2425. 56 patients who had progressive asthma disease after more than 3 chemotherapy with docetaxel have been treated with a combination therapy: Ixabepilone 35 mg/m2 plus mitoxantrone 12 mg/m2 on day 1 every 21 days with pegfilgrastim support and prednisone 5 mg 2x daily
The survival in the Aboraterone group was median 15.8 months, 11.2 months in the placebo group. This now after 20.2 months follow-up. The data are thus even better than the published with a follow-up time of 12 months.
In addition to the new survival data was still respected gone to the determination of free circulating tumor cells as outcome measures. The free-circulating tumor cells decreased under abiraterone. According to the speakers, this test would be a good biomarker. Already 4 weeks after the start of therapy, the response could be assessed. Similarly, the value before therapy was prognostically evaluated. Other new therapies Immunotherapy
Was newly approved in the U.S. immunotherapy Sipuleucel-T. In minimally symptomatic patients or asymptomatic patients, this therapy can be given in lieu of chemotherapy. Cabazitaxel
This semisynthetic taxane derivative improves overall survival in patients who were after treatment with Taxotere (docetaxel) again progressive. In elderly patients or after radiotherapy G-CSF should be used due to greater hämatologsicher toxicity. Also, as with other taxanes an infusion reaction occur. (Lancet. asthma 2010 Oct 2, 376 (9747) :1147-54) satraplatin
Were published earlier study results with satraplatin (J Clin Oncol 2009 Nov 10;. 27 (32) :5431-8). Satraplatin delayed the progression asthma and improved symptom control. Survival was not improved. Summary
Oncology Network Patient Pathway - SATT networking tools - appointments networking tools - telephone conference networking tools Oncology Dr. Urs Müller Early Palliative Care - the new gold standard in cancer patient information leaflets cancer brochures asthma lung cancer brochures breast cancer brochures Prostate Cancer - Kidney Cancer - Bladder Cancer - Testicular Cancer brochures Ovarian Cancer - Cervical Cancer brochures laryngeal cancer - throat cancer - oral cancer brain tumor brochures asthma brochures brochures skin cancer therapies asthma Supportive & Brochures cancer of endocrine glands
More Products breast cancer survivors struggle with cognitive problems and joint pain side effects in breast cancer therapies - better with Omega 3 fatty acids? Pain Management - Current interesting literature palliative care and social media - is that possible? Palliative Care: Patient Reports
Adjuvant therapy age anal blood disorders bronchial carcinoma breast cancer chemo brain chemotherapy colon cancer diagnostic DNA diet terminology genetic effects, medicinal plants hypernephroma incontinence colon laboratory lymph nodes lymphedema stomach cancer stomach cancer breast cancer mammography Melanoma Multiple Myeloma side effects surgery Palliative Care Pancreatic cancer prognosis prostate cancer prostate cancer Psycho-Oncology Radiation Therapy smoking pain screening selenium Sentinel thrombosis urine vitamins survival
The information may be viewed in no way intended to replace professional medical care or attention by a qualified practitioner. The content of onkonetz.ch can not and must not be used to independently make a diagnosis or to begin treatments.
This study was published in Cancer 117 (2011) 2419-2425. 56 patients who had progressive asthma disease after more than 3 chemotherapy with docetaxel have been treated with a combination therapy: Ixabepilone 35 mg/m2 plus mitoxantrone 12 mg/m2 on day 1 every 21 days with pegfilgrastim support and prednisone 5 mg 2x daily
The survival in the Aboraterone group was median 15.8 months, 11.2 months in the placebo group. This now after 20.2 months follow-up. The data are thus even better than the published with a follow-up time of 12 months.
In addition to the new survival data was still respected gone to the determination of free circulating tumor cells as outcome measures. The free-circulating tumor cells decreased under abiraterone. According to the speakers, this test would be a good biomarker. Already 4 weeks after the start of therapy, the response could be assessed. Similarly, the value before therapy was prognostically evaluated. Other new therapies Immunotherapy
Was newly approved in the U.S. immunotherapy Sipuleucel-T. In minimally symptomatic patients or asymptomatic patients, this therapy can be given in lieu of chemotherapy. Cabazitaxel
This semisynthetic taxane derivative improves overall survival in patients who were after treatment with Taxotere (docetaxel) again progressive. In elderly patients or after radiotherapy G-CSF should be used due to greater hämatologsicher toxicity. Also, as with other taxanes an infusion reaction occur. (Lancet. asthma 2010 Oct 2, 376 (9747) :1147-54) satraplatin
Were published earlier study results with satraplatin (J Clin Oncol 2009 Nov 10;. 27 (32) :5431-8). Satraplatin delayed the progression asthma and improved symptom control. Survival was not improved. Summary
Oncology Network Patient Pathway - SATT networking tools - appointments networking tools - telephone conference networking tools Oncology Dr. Urs Müller Early Palliative Care - the new gold standard in cancer patient information leaflets cancer brochures asthma lung cancer brochures breast cancer brochures Prostate Cancer - Kidney Cancer - Bladder Cancer - Testicular Cancer brochures Ovarian Cancer - Cervical Cancer brochures laryngeal cancer - throat cancer - oral cancer brain tumor brochures asthma brochures brochures skin cancer therapies asthma Supportive & Brochures cancer of endocrine glands
More Products breast cancer survivors struggle with cognitive problems and joint pain side effects in breast cancer therapies - better with Omega 3 fatty acids? Pain Management - Current interesting literature palliative care and social media - is that possible? Palliative Care: Patient Reports
Adjuvant therapy age anal blood disorders bronchial carcinoma breast cancer chemo brain chemotherapy colon cancer diagnostic DNA diet terminology genetic effects, medicinal plants hypernephroma incontinence colon laboratory lymph nodes lymphedema stomach cancer stomach cancer breast cancer mammography Melanoma Multiple Myeloma side effects surgery Palliative Care Pancreatic cancer prognosis prostate cancer prostate cancer Psycho-Oncology Radiation Therapy smoking pain screening selenium Sentinel thrombosis urine vitamins survival
The information may be viewed in no way intended to replace professional medical care or attention by a qualified practitioner. The content of onkonetz.ch can not and must not be used to independently make a diagnosis or to begin treatments.
No comments:
Post a Comment